Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip's Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharma industry.

A new bite-size podcast provides a brief audio tour around Scrip's Five Must-Know Things, starting off for the week ended 19 July.

This time we provide easy to digest updates around Operation Warp Speed, diversity in the biopharma industry, shifting commercial models, new results in psoriasis, and the future of cell and gene therapies.

Stories mentioned in this podcast:

(Also see "Operation Warp Speed Shortlist Not Decided Yet, Says Novavax" - Scrip, 15 Jun, 2020.)

(Also see "Leading A Diverse Company: Biopharma Executives Offer Ways Forward" - Scrip, 12 Jun, 2020.)

(Also see "Commercial Models Shifting As Pharma Mulls Digital-First Launches" - Scrip, 16 Jun, 2020.)

(Also see "Can UCB's Bimekizumab Go From Last To First In Psoriasis?" - Scrip, 15 Jun, 2020.)

(Also see "The Future Of Medicine: Cell And Gene Therapies Take The Lead" - Scrip, 11 Jun, 2020.)






Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts